SUPERNUS PHARMACEUTICALS, INC. (SUPN) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$42.76

From 52W high−26.32%

Volume1.18M

Market cap$2.45B

P/E (TTM)—

P/S (TTM)2.9x

Div yield—

Key dataSep 18, 2026

Open

$42.76

From 52W high

−26.32%

Volume

1.18M

Market cap

$2.45B

ValuationView details →

P/E (Fwd)

14.5x

EV/EBITDA

−133.2x

P/E (TTM)

—

RSI (14)

37.7

MomentumView details →

1D Return

−2.14%

YTD Return

−15.97%

SummaryUpdated Jun 1, 2026

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is a biopharmaceutical company founded in 2005 and headquartered in Rockville, Maryland. The company went public in 2012 and specializes in developing and commercializing treatments for central nervous system (CNS) disorders. Supernus has evolved from a company dependent on legacy epilepsy medications to one focused on growth products, particularly in ADHD and Parkinson's disease treatments. The company operates primarily in the United States market and has built a portfolio of both commercial products and pipeline candidates targeting various neurological and psychiatric conditions.

Ask drillr about SUPERNUS PHARMACEUTICALS, INC. →

ValuationView details →

P/E (Fwd)

14.5x

P/E (TTM)

—

EV/EBITDA

−133.2x

EV/Sales

2.5x

P/S (TTM)

2.9x

P/B (TTM)

2.4x

ProfitabilityView details →

Gross Margin

88.07%

Net Margin

−13.23%

EBITDA Margin

−1.91%

ROE (TTM)

−10.66%

ROA (TTM)

−7.69%

Asset Turnover

0.57x

GrowthView details →

Revenue YoY

+24.85%

EPS YoY

—

FCF YoY

−89.89%

Revenue CAGR 3Y

+2.52%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−2.14%

YTD Return

−15.97%

1Y Return

−9.29%

RSI (14)

37.7

vs 50D SMA

−8.41%

vs 200D SMA

−13.61%

Capital & dividendView details →

Debt/Equity

0.04x

Current Ratio

2.08x

Quick Ratio

1.84x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.54

EPS Surprise

27.81%

Beats (12Q)

5/12

Next Q EPS Est

$0.62

Avg Surprise (4Q)

−6376.14%

Rev Surprise

6.70%

Financials snapshotView financials →

Revenue (TTM)

830.44M

Net Income (TTM)

−109.89M

Op. CF (TTM)

19.91M

Next earningsNov 3, 2026 →

Latest newsMore news →

Supernus Pharmaceuticals announced a compensated ambassador partnership with professional snowboarder Chloe Kim to discuss her ADHD journey and treatment with Qelbree.20d ago

Assenagon Asset Management S.A. reduced its stake in Supernus Pharmaceuticals, Inc. by 86.2% during the quarter, selling 457,443 shares and retaining 73,175 shares, as disclosed in a 13F filing.38d ago

Similar companies

Hua Medicine (Shanghai) Ltd.02552.HK 圣达生物603079.SH HUTCHMED (China) LimitedHCM Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.01349.HK ST交昂600530.SH Chia Tai Enterprises International Limited03839.HK Find similar companies →

Latest newsMore news →

Supernus Pharmaceuticals announced a compensated ambassador partnership with professional snowboarder Chloe Kim to discuss her ADHD journey and treatment with Qelbree.20d ago Assenagon Asset Management S.A. reduced its stake in Supernus Pharmaceuticals, Inc. by 86.2% during the quarter, selling 457,443 shares and retaining 73,175 shares, as disclosed in a 13F filing.38d ago